{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:25:10Z","timestamp":1782908710815,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>As the opioid public health crisis evolves to include fentanyl and other potent synthetic opioids, more patients are admitted to the hospital with serious complications of drug use and frequently require higher levels of care, including intensive care unit (ICU) admission, for acute and chronic conditions related to opioid use disorder (OUD). This patient population poses a unique challenge when managing sedation and ensuring adequate ventilation while intubated given their high opioid requirements. Starting a patient on medications such as buprenorphine may be difficult for inpatient providers unfamiliar with its use, which may lead to undertreatment of patients with OUD, prolonged mechanical ventilation and length of stay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We developed a 7-day buprenorphine low dose overlap initiation (LDOI) schedule for patients with OUD admitted to the ICU (Table\u00a01). Buprenorphine tablets were split by pharmacists and placed into pre-made blister packs as a kit to be loaded into the automated medication dispensing machine for nursing to administer daily. An internal quality review validated the appropriate dosing of split-dose tablets. To simplify order entry and increase prescriber comfort with this new protocol, we generated an order set within our electronic health record software with prebuilt buprenorphine titration orders. This protocol was implemented alongside patient and healthcare team education and counseling on the LDOI process, with follow-up offered to all patients upon discharge.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Here we report a series of 6 ICU patients started on buprenorphine using the LDOI schedule with split buprenorphine tablets. None of the 6 patients experienced precipitated withdrawal upon buprenorphine initiation using the LDOI schedule, and 5\/6 patients were successfully extubated during the buprenorphine initiation. Four of six patients had a decrease in daily morphine milligram equivalents, with 3 patients transitioning to buprenorphine alone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Initiating buprenorphine via LDOI was found to be successful in the development of a protocol for critically ill patients with OUD. We examined LDOI of buprenorphine in intubated ICU patients and found no events of acute precipitated withdrawal. This protocol can be used as a guide for other institutions seeking to start critically ill patients on medication treatment for OUD during ICU admission.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01028-4","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T07:02:06Z","timestamp":1717743726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder"],"prefix":"10.1186","volume":"21","author":[{"given":"Laura","family":"Szczesniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa Baxter","family":"RN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"1028_CR1","unstructured":"CDC. WONDER Online Database. 2023."},{"issue":"8","key":"1028_CR2","first-page":"e9788","volume":"12","author":"AO Oladunjoye","year":"2020","unstructured":"Oladunjoye AO, Oladunjoye OO, Olubiyi O, Yee MR, Espiridion ED. Predictors and outcomes of Invasive Mechanical Ventilation in Opioid Overdose hospitalization in the United States. Cureus. 2020;12(8):e9788.","journal-title":"Cureus"},{"issue":"3","key":"1028_CR3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1213\/ANE.0000000000003307","volume":"127","author":"P Sayal","year":"2018","unstructured":"Sayal P, Bateman BT, Menendez M, Eikermann M, Ladha KS. Opioid Use disorders and the risk of postoperative pulmonary complications. Anesth Analg. 2018;127(3):767\u201374.","journal-title":"Anesth Analg"},{"issue":"3","key":"1028_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamasurg.2018.4608","volume":"154","author":"KC Dewan","year":"2019","unstructured":"Dewan KC, Dewan KS, Idrees JJ, Navale SM, Rosinski BF, Svensson LG, et al. Trends and outcomes of Cardiovascular surgery in patients with opioid Use disorders. JAMA Surg. 2019;154(3):232\u201340.","journal-title":"JAMA Surg"},{"issue":"12","key":"1028_CR5","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.2105\/AJPH.2015.302885","volume":"105","author":"L Ti","year":"2015","unstructured":"Ti L, Ti L. Leaving the hospital against medical advice among people who use Illicit drugs: a systematic review. Am J Public Health. 2015;105(12):e53\u20139.","journal-title":"Am J Public Health"},{"key":"1028_CR6","doi-asserted-by":"crossref","unstructured":"Krawczyk N, Rivera BD, Basaraba C, Corbeil T, Allen B, Schultebraucks K et al. COVID-19 complications among patients with opioid use disorder: a retrospective cohort study across five major NYC hospital systems. Addiction. 2022.","DOI":"10.1111\/add.16105"},{"issue":"6","key":"1028_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.5055\/jom.2022.0747","volume":"18","author":"HF Thiesset","year":"2022","unstructured":"Thiesset HF, Newman M, Tonna JE, Merrill RM. Outcomes of patients with COVID-19 in the setting of chronic opioid use disorder. J Opioid Manag. 2022;18(6):523\u20138.","journal-title":"J Opioid Manag"},{"issue":"2","key":"1028_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/jat\/bkad089","volume":"48","author":"J Martinez","year":"2024","unstructured":"Martinez J, Gonyea J, Zaney ME, Kahl J, Moore DM. The evolution of fentanyl-related substances: prevalence and drug concentrations in postmortem biological specimens at the Miami-Dade Medical Examiner Department. J Anal Toxicol. 2024;48(2):104\u201310.","journal-title":"J Anal Toxicol"},{"key":"1028_CR9","doi-asserted-by":"publisher","first-page":"1046648","DOI":"10.3389\/fpsyt.2022.1046648","volume":"13","author":"A Sivils","year":"2022","unstructured":"Sivils A, Lyell P, Wang JQ, Chu XP. Suboxone: history, controversy, and open questions. Front Psychiatry. 2022;13:1046648.","journal-title":"Front Psychiatry"},{"key":"1028_CR10","doi-asserted-by":"publisher","first-page":"108410","DOI":"10.1016\/j.jsat.2021.108410","volume":"130","author":"RW Sullivan","year":"2021","unstructured":"Sullivan RW, Szczesniak LM, Wojcik SM. Bridge clinic buprenorphine program decreases emergency department visits. J Subst Abuse Treat. 2021;130:108410.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"1028_CR11","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/ADM.0000000000000864","volume":"16","author":"D Button","year":"2022","unstructured":"Button D, Hartley J, Robbins J, Levander XA, Smith NJ, Englander H. Low-dose buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis. J Addict Med. 2022;16(2):e105\u201311.","journal-title":"J Addict Med"},{"issue":"6","key":"1028_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/ADM.0000000000000675","volume":"14","author":"B Hamata","year":"2020","unstructured":"Hamata B, Griesdale D, Hann J, Rezazadeh-Azar P. Rapid Micro-induction of Buprenorphine\/Naloxone for Opioid Use Disorder in a critically ill intubated patient: a Case Report. J Addict Med. 2020;14(6):514\u20137.","journal-title":"J Addict Med"},{"issue":"2","key":"1028_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","volume":"35","author":"DR Wesson","year":"2003","unstructured":"Wesson DR, Ling W. The clinical opiate Withdrawal Scale (COWS). J Psychoact Drugs. 2003;35(2):253\u20139.","journal-title":"J Psychoact Drugs"},{"issue":"4","key":"1028_CR14","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1097\/ADM.0000000000001154","volume":"17","author":"M Noel","year":"2023","unstructured":"Noel M, Abbs E, Suen L, Samuel L, Dobbins S, Geier M, et al. The Howard Street Method: A Community Pharmacy-led low dose overlap buprenorphine initiation protocol for individuals using fentanyl. J Addict Med. 2023;17(4):e255\u201361.","journal-title":"J Addict Med"},{"issue":"10","key":"1028_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/phar.2313","volume":"39","author":"D Terasaki","year":"2019","unstructured":"Terasaki D, Smith C, Calcaterra SL. Transitioning hospitalized patients with opioid Use Disorder from Methadone to Buprenorphine without a period of opioid abstinence using a Microdosing Protocol. Pharmacotherapy. 2019;39(10):1023\u20139.","journal-title":"Pharmacotherapy"},{"key":"1028_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/SAR.S109919","volume":"7","author":"R Hammig","year":"2016","unstructured":"Hammig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99\u2013105.","journal-title":"Subst Abuse Rehabil"},{"issue":"3","key":"1028_CR17","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1503\/cmaj.74018","volume":"192","author":"PA Randhawa","year":"2020","unstructured":"Randhawa PA, Brar R, Nolan S. Buprenorphine-naloxone microdosing: an alternative induction approach for the treatment of opioid use disorder in the wake of North America\u2019s increasingly potent illicit drug market. CMAJ. 2020;192(3):E73.","journal-title":"CMAJ"},{"issue":"4","key":"1028_CR18","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ajad.12869","volume":"28","author":"S Klaire","year":"2019","unstructured":"Klaire S, Zivanovic R, Barbic SP, Sandhu R, Mathew N, Azar P. Rapid micro-induction of buprenorphine\/naloxone for opioid use disorder in an inpatient setting: a case series. Am J Addict. 2019;28(4):262\u20135.","journal-title":"Am J Addict"},{"issue":"1","key":"1028_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13722-021-00220-2","volume":"16","author":"JSH Wong","year":"2021","unstructured":"Wong JSH, Nikoo M, Westenberg JN, Suen JG, Wong JYC, Krausz RM, et al. Comparing rapid micro-induction and standard induction of buprenorphine\/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. Addict Sci Clin Pract. 2021;16(1):11.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"1028_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13722-020-0177-x","volume":"15","author":"J Rozylo","year":"2020","unstructured":"Rozylo J, Mitchell K, Nikoo M, Durante SE, Barbic SP, Lin D, et al. Case report: successful induction of buprenorphine\/naloxone using a microdosing schedule and assertive outreach. Addict Sci Clin Pract. 2020;15(1):2.","journal-title":"Addict Sci Clin Pract"},{"issue":"6","key":"1028_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.9740\/mhc.2021.11.369","volume":"11","author":"S Menard","year":"2021","unstructured":"Menard S, Jhawar A. Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: a case report. Ment Health Clin. 2021;11(6):369\u201372.","journal-title":"Ment Health Clin"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01028-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01028-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01028-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T07:07:12Z","timestamp":1717744032000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01028-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1028"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01028-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was developed and implemented as part of a quality improvement project and received ethical approval from Upstate Medical University Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}